Pharmacological management of the agitated pediatric patient

Pediatric Emergency Care

Volumn 26, Issue 11, 2010, Pages 856-860

  Adimando, Andrea J ^a,b   Poncin, Yann B ^a,c   Baum, Carl R ^a,d  

^a YALE NEW HAVEN CHILDREN S HOSPITAL   (United States)

^b Yale Psychiatric Hospital   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

agitation; behavioral; pharmacological management; pharmacology; psychiatry

Indexed keywords

CHLORPROMAZINE; DIPHENHYDRAMINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; RISPERIDONE;

AGITATION; BEHAVIOR DISORDER; CHILD CARE; CONTINUING EDUCATION; DISINHIBITION; DRUG METABOLISM; DYSTONIA; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPOTENSION; MEDICAL EDUCATION; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARADOXICAL DRUG REACTION; PATIENT CARE; PHARMACEUTICAL CARE; PSYCHOLOGIC ASSESSMENT; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEIZURE; TACHYCARDIA; VIOLENCE; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; EMERGENCY SERVICE, HOSPITAL; HUMANS; PSYCHOMOTOR AGITATION; RISK ASSESSMENT;

EID: 78649388839     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e3181f9dce4     Document Type: Review

References (24)

1. Briggs-Gowan MJ, Horwitz SM, Schwab-Stone ME, et al. Mental health in pediatric settings: distribution of disorders and factors related to service use. J Am Acad Child Adolesc Psychiatry. 2000;39(7):841-849.
2. Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolesc Psychiatry. 1996;35(7):865-877.
3. Sills M, Bland S. Summary statistics for pediatric psychiatric visits to US emergency departments, 1993-1999. Pediatrics. 2002;110(4):e40-e40.
4. Thomas L. Trends and shifting ecologies: Part I. Child Adolesc Psychiatr Clin N Am. 2003;12(4):599-611.
5. Brasch JS, Ferencz JC. Training issues in emergency psychiatry. Psychiatr Clin N Am. 1999;22(4):941-954,x.
6. Weissberg M. The meagerness of physicians' training in emergency psychiatric intervention. Acad Med. 1990;65(12):747-750.
7. Rocca P, Villari V, Bogetto F. Managing the aggressive and violent patient in the psychiatric emergency. Progr Neuropsychopharmacol Biol Psychiatry. 2006;30(4):586-598.
8. Office of the Surgeon General. Risk factors for youth violence. In: Youth Violence: A Report of the Surgeon General. Washington, DC: Department of Health and Human Servies; 2001.
9. Giggie M, Olvera R, Joshi M. Screening for risk factors associated with violence in pediatric patients presenting to a psychiatric emergency department. J Psychiatr Pract. 2007;13(4):246-252.
10. Szuster RR, Schanbacher BL, McCann SC. Characteristics of psychiatric emergency room patients with alcohol-or drug-induced disorders. Hosp Community Psychiatry. 1990;41(12):1342-1345.
11. Mossman D. Assessing predictions of violence: being accurate about accuracy. J Consult Clin Psychol. 1994;62(4):783-792. (Pubitemid 24268721)
12. Sadka S. Psychiatric emergencies in children and adolescents. New Dir Ment Health Serv. 1995;(67):65-74.
13. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61(suppl 14):11-20.
14. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry. 2000;61(suppl 14):5-10.
15. Gerstenzang ML, Krulisky TV. Parenteral haloperidol in psychiatric emergencies. Double-blind comparison with chlorpromazine. Dis Nerv Syst. 1977;38(8):581-583.
16. Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):405-413.
17. Currier G, Chou JCY, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004;65(3):386-394.
18. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876-1885.
19. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev. 2005;2:CD003729.
20. Kamin J, Manwani S, Hughes D. Emergency psychiatry: extrapyramidal side effects in the psychiatric emergency service. Psychiatr Serv. 2000;51(3):287-289.
21. Dubin WR, Weiss KJ, Dorn JM. Pharmacotherapy of psychiatric emergencies. J Clin Psychopharmacol. 1986;6(4):210-222.
22. Satterthwaite T, Wolf D, Rosenheck R, et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869-1879.
23. Van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999;319(7210):623-626.
24. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997;15(4):335-340.